VYNE Therapeutics (VYNE) Gross Margin (2019 - 2021)
VYNE Therapeutics (VYNE) posted Gross Margin of 230.77% for Q4 2021, up 66.49% on a QoQ basis from 688.72% in Q3 2021, and down 31831.0% year-over-year from N/an in Q4 2020.
VYNE Therapeutics (VYNE) Gross Margin (2019 - 2021) Analysis & Trends
VYNE Therapeutics' Gross Margin history runs 3 years deep, the most recent figure standing at 230.77% for Q4 2021.
- Quarterly Gross Margin fell 31831.0% year-over-year to 230.77% in Q4 2021, while the trailing twelve-month figure through Dec 2021 was 259.61% (down 35298.0% YoY) and the FY2021 annual result came in at 259.61%, down 35298.0% from the prior year.
- Gross Margin was 230.77% for Q4 2021 at VYNE Therapeutics, up from 688.72% in the prior quarter.
- Across five years, Gross Margin topped out at 100.0% in Q4 2019 and bottomed at 688.72% in Q3 2021.
- A 3-year average of 87.94% and a median of 84.51% in 2020 frame the typical range for Gross Margin.
- Annual changes were most pronounced in 2020 — Gross Margin plunged 1246 bps — and 2021, when it slumped 77737 bps.
- VYNE Therapeutics' Gross Margin stood at 100.0% in 2019, then dropped by 12 bps to 87.54% in 2020, then tumbled by 364 bps to 230.77% in 2021.
- Business Quant data shows VYNE's Gross Margin at 230.77% in Q4 2021, 688.72% in Q3 2021, and 169.49% in Q2 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 88.95% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 86.85% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 91.79% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 90.68% |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | VYNE Therapeutics | 1.19 Bn | 1.16 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | -230.77% |
| Sep 30, 2021 | -688.72% |
| Jun 30, 2021 | -169.49% |
| Mar 31, 2021 | -161.30% |
| Dec 31, 2020 | 87.54% |
| Sep 30, 2020 | 88.65% |
| Jun 30, 2020 | 98.15% |
| Mar 31, 2020 | 84.51% |
| Dec 31, 2019 | 100.00% |